Calcitonin, an important factor in the calcemic response to parathyroid hormone in the rat  by Rodriguez, Mariano et al.
Kidney International, Vol. 40 (1991), pp. 2 19—225
Calcitonin, an important factor in the calcemic response to
parathyroid hormone in the rat
MARIANO RODRIGUEZ, ARNOLD J. FELSENFELD, ARMANDO TORRES', LEE PEDERSON2,
and FrJiNcIsco LLACH
Department of Medicine, Wadsworth VA Medical Center and UCLA, Los Angeles, California, USA
Calcitonin, an important factor in the calcemic response to parathyroid
hormone in the rat. The role of calcitonin on the calcemic response to
parathyroid hormone (PTH) in renal failure has not been evaluated
previously. Often animal studies evaluating the calcemic response to
PTH in renal failure are performed in thyroparathyroidectomized
(TPTX) animals, and thus eliminate any potential physiologic effect of
calcitonin. In addition, parathyroidectomy (PTX), presumably by re-
duction of high PTH levels, has corrected the calcemic response to PTH
in animals with renal failure. The present study was designed to
evaluate the effect of endogenous calcitonin production on the calcemic
response to PTH in rats with renal failure and secondary hyperparathy-
roidism, and in rats with normal renal function with diet induced
hyperparathyroidism. Four groups of rats were evaluated: I) chronic
renal failure plus TPTX with autotranspiant of the parathyroid gland,
(CT—) CRF; 2) chronic renal failure plus selective PTX with autotrans-
plant of the parathyroid gland, (CT+) CRF; 3) normal renal function
plus TPTX with autotransplant of the parathyroid gland, (CT—) NRF;
and 4) normal renal function plus selective PTX with autotransplant of
the parathyroid gland, (CT+) NRF. Renal failure was surgically in-
duced by a two-stage 5/6 nephrectomy, and exogenous thyroxine was
administered to the two thyroidectomized (CT—) groups. Hyperpara-
thyroidism was induced with a high phosphate diet (1.2%), and thus at
the time of PTH infusion, PTH levels were (CT—) CRF 84 16, (CT+)
CRF 89 21, (CT—) NRF 37 7, and (CT+) NRF 31 4 pg/mI,
respectively (normal 21 3 pg/mI). Rat 1-34 PTH (2.6 U/hr) was infused
for 48 hours via a subcutaneously implanted Alzet pump. The increase
in serum calcium was: 7.56 .73 (CT—) CRF versus 4.01 .48 mg/dl(CT+) CRF, P < 0.002; and 7.56 .34 (CT—) NRF versus 5.85 .48
mg/dl (CT+) NRF, P < 0.02. In summary, in rats with hyperparathy-
roidism, the absence of calcitonin: I) increased the calcemic response
to PTH both in rats with and without renal failure; and 2) resulted in a
similar calcemic response to PTH in rats with and without renal failure.
In conclusion, in renal failure, calcitonin is an important factor in the
decreased calcemic response to PTH in rats with PTH induced hyper-
calcemia.
Calcitonin is a 32-amino acid peptide hormone that is synthe-
sized and secreted by the C-cells of the thyroid gland 11, 2].
Studies in animals and humans have shown that acute hyper-
calcemia stimulates calcitonin secretion [3—5]. Although the
original descriptions viewed calcitonin as a calcium lowering
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hormone, its precise role in calcium regulation remains contro-
versial more than 25 years after its discovery [6, 7].
In renal failure, a condition in which secondary hyperpara-
thyroidism is normally present, skeletal resistance to the calce-
mic action of parathyroid hormone (PTH) is a well known
finding [8—12]. Several factors have been implicated in this
skeletal resistance to the calcemic action of PTH. These include
hyperphosphatemia [10], decreased calcitriol levels [11], and
down regulation of bone receptors for PTH, a consequence of
high PTH levels [12]. In many of these studies [10—12], a total
thyroparathyroidectomy was performed before the infusion of
PTH. Thus, the potential role of calcitonin on the modification
of the calcemic response to P1'H was not considered. In
addition, in animals with normal renal function, studies have
not conclusively determined whether the presence of calcitonin
affects the development of hypercalcemia [3, 13—171. Further-
more, with normal renal function, the role of calcitonin in P1'H
induced hypercalcemia has not been defined in the presence of
hyperparathyroidism.
Our primary purpose was to evaluate in renal failure whether
endogenous calcitonin production modified the calcemic re-
sponse to PTH. In addition, the effect of endogenous calcitonin
production on the calcemic response to P1'H was also evaluated
in rats with normal renal function and diet induced hyperpara-
thyroidism.
Methods
Four groups of male Wistar rats weighing 150 to 200 grams
were studied. The rats were pair-fed and during the study, no
differences in weight gain were observed between the four
groups. A schematic diagram of the study protocol is shown in
Figure 1. Group (CT—) CRF (N = 9) had a thyroparathyroidec-
tomy (TPTX) with parathyroid gland autotransplant on Day 0;
from Days 10 to 15, a two-stage 5/6 nephrectomy was per-
formed. Group (CT+) CRF (N = 8) had a selective parathy-
roidectomy (PTX) with autotranspiantation of the parathyroid
gland on Day 0; from Days 10 to 15, a two-stage 5/6 nephrec-
tomy was performed. Group (CT—) NRF (N = 8) had a TPTX
with parathyroid gland autotransplant on Day 0. Group (CT+)
NRF (N = 9) had a selective PTX with parathyroid gland
autotransplant on Day 0. In all four groups, the parathyroid
glands were autotransplanted to the sternocleidomastoid mus-
cle. In the two groups subjected to thyroidectomy, (CT—) CRF
and (CT—) NRF, 1 jzg of subcutaneous thyroxine was given
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Fig. 1. A schema of the experimental design
is shown. The study was from Days 0 to 30.
The calcium and phosphate content of the diet
was changed as shown. Groups (CT—) CRF
and (CT—) NRF had a thyroidectomy on Day
0 which removed calcitonin production.
Groups (CT+) CRF and (CT+) NRF had
intact thyroid glands. All 4 groups had a total
parathyroidectomy and autotranspiantation of
the parathyroid glands on Day 0. All 4 groups
were placed on a calcium free diet from Days
5 through 10 to evaluate the function of the
autotranspianted parathyroid glands. Groups(CT—) CRF and (CT+) CRF underwent a 2-
stage 5/6 nephrectomy from Days 10 to 15. On
Day 16, all 4 groups were placed on a high
phosphate diet to induce hyperparathyroidism.
On Day 28, an Alzet pump containing 1-34 rat
PTH was implanted subcutaneously in all
groups. During the PTH infusion all groups
were placed on a calcium free diet. Groups
(CT—) CRF and (CT—) NRF received
supplemental thyroxine during the study
period.
three times per week. To validate the adequate function of the
parathyroid gland autotranspiant, all rats were placed on cal-
cium free diet from Days 5 to 10, and only rats which main-
tained a serum calcium greater than 9 mgldl were included in the
study. On Day 16, to induce marked secondary hyperparathy-
roidism, all rats were placed on a high phosphate diet (phos-
phate 1.2%, calcium 0.6%). On Day 28, rat 1-34 PTH (Bachem,
Torrance, California, USA) was infused via a subcutaneously
implanted Aizet pump (model 2001) at 2.6 U/hour for 48 hours.
During the PTH infusion, rats were placed on a calcium free,
low phosphate diet (calcium 0%, phosphate 0.16%). This diet
was used to minimize any gastrointestinal absorption of calcium
and phosphate during the PTH infusion. Blood for calcium,
phosphorus, and creatinine was obtained at 0, 24, and 48 hours.
During the PTH infusion, rats were placed in a metabolic cage
and urine collected for calcium, phosphorus, and creatinine.
Each Aizet pump was used in three rats; after a 48-hour PTH
infusion, the Aizet pump was removed from one rat and placed
subcutaneously in another rat from a different group.
Serum and urinary calcium was measured by atomic absorp-
tion (Model 5300, Perkin Elmer, Norwalk, Connecticut, USA),
phosphorus by a colorimetric method (Fast Phosphorus Test
Set, Stanbio, San Antonio, Texas, USA), and creatinine by a
specific analyzer (Creatinine Analyzer 2, Beckman Instru-
ments, Fullerton, California, USA). Parathyroid hormone was
determined with a N-terminal radioimmunoassay kit (Nichols,
San Juan Capistrano, California, USA) which measures rat
PTH [18, 19]. Parathyroid hormone levels obtained in normal
rats with similar weights and receiving the same diet as rats in
the early phase of this study (calcium 1.2%, phosphate 0.9%),
were 21 3 pg/mI [19, 20]. Calcitonin was measured with a
radioimmunoassay kit (Nichols). In a previous study, the suit-
ability of this assay for measuring rat calcitonin was docu-
mented [211. In that study, serum calcitonin levels in thyropara-
thyroidectomized rats were 6.9 pg/mI.
Statistics
Biochemical data were analyzed using one-way analysis of
variance. The Bonferroni test was applied when multiple corn-
Table 1. Serum calcium, phosphorus, and creatinine
Serum calcium mg/dl
PTH
Day 28 Infusion Day 30
Groups Day 10 0 hr 24 hr 48 hr
(CT—) CRF 9.8 (0.3)a 8.3 (0.4) 14.8 (0.5) 15.8 (0.5)
(CT+) CRF 9.7 (0.3)a 8.8 (0.6) 10.4 (02)b 12.8 (0,4)b
(CT—) NRF 9.5 (0.3) 9.4 (0.2) 15.2 (0.5) 17.0 (0.3)
(CT+) NRF 9.7 (0.2) 9.5 (0.2) 12.7 (0.7)c 15,4 (0.5)
Serum phosphorus mg/dl
(CT—) CRF 12.1 (1.0) 8.2 (0.4) 7.7 (0.4)
(CT+) CRF 9.6 (1.1) 5.2 (0,5)b 6.6 (03)b
(CT—) NRF 10.5 (0.2) 6.1 (0.3) 7.7 (0.7)
(CT+) NRF 10.3 (0.4) 6.7 (0.3) 6.9 (0.4)
Serum creatinine mg/dl
(CT—) CRF 1.0 (0.10) 0.9 (0.06) 1.1 (0.08)
(CT+) CRF 0.8 (003)b 0.7 (008)b 0.7 (008)b
(CT—) NRF 0.4 (0.06) 0.5 (0.04) 0.8 (0.09)
(CT+) NRF 0.3 (0.02) 0.4 (0.04) 0.6 (0.12)
i Serum calcium mg/dl
(CT—) CRF 6.6 (0.4) 7.6 (0.7)
(CT+) CRF 1.6 (05)b 4.0 (05)b
(CT—) NRF 5.8 (0.6) 7.6 (0.3)
(CT+) NRF 3.2 (0.8)c 5.9 (0.5)c
Data are presented as mean SE.
P < 0.05 vs. Day 28
b P < 0.05 vs. (CT—) CRF at same time interval
P < 0.05 vs. (CT—) NRF at same time interval
parisons were performed. Statistical differences were further
investigated by utilization of the unpaired t-test, in which a P
value < 0.05 was considered statistically significant. All values
shown are the mean standard error (SE).
Results
The serum calcium, phosphorus, creatinine, and the P'I'H
induced increase in serum calcium for the four groups are
shown in Table I. On Day 10, after five days of a calcium free
diet and before nephrectomy in the (CT—) CRF and (CT+) CRF
groups, the serum calcium levels were similar in all groups. At
Days 0 5 10 15
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Fig. 2. The PTH levels on Day 28, immediately before the PTH
infusion, are shown. Hyperparathyroidism was induced by a combina-
tion of renal failure and a high phosphate diet, or in the two groups with
normal renal function by a high phosphate diet. The PTH levels for the
two groups with renal failure, (CT—) CRF and (CT+) CRF, were not
significantly different; similar results were observed in the two groups
with normal renal function, (CT—) NRF and (CT+) NRF. Values are
the mean SE.
the start of the PTH infusion, Day 28, serum calcium levels
were lower in rats with renal failure, but there were no
significant differences between the two groups with renal fail-
ure, (CT—) CRF versus (CT+) CRF, and the two groups with
normal renal function, (CT—) NRF versus (CT+) NRF. On Day
28, at the start of the PTH infusion, no significant differences
were observed in serum phosphorus levels, (CT—) CRF versus
(CT+) CRF, and (CT—) NRF versus (CT+) NRF. The serum
creatinine was similar in the two groups with normal renal
function, (CT—) NRF versus (CT+) NRF. In the two groups
with renal failure, the serum creatinine was minimally increased
in the group with thyroidectomy, (CT—) CRF versus (CT+)
CRF. As shown in Figure 2, on Day 28, immediately before the
PTH infusion, the serum PTH levels were higher in the groups
with renal failure, but no differences were found between the
two groups with renal failure, (CT—) CRF versus (CT+) CRF,
and the two groups without renal failure, (CT—) NRF versus
(CT+) NRF.
The effect of the PTH infusion on serum calcium is shown in
Table 1 and Figure 3. At both 24 and 48 hours, the increase in
serum calcium was greater in thyroidectomized (CT—) than
thyroid intact (CT+) rats both in rats with renal failure and rats
with normal renal function. As shown in Table 1 and Figure 4,
at both 24 and 48 hours, the serum phosphorus concentration
was greater in the (CT—) CRF than the (CT+) CRF group; no
differences were observed in the two groups with normal renal
function. After 48 hours of a PTH infusion, the two groups with
the greatest hypercalcemia, (CT—) CRF and (CT—) NRF,
tended to have a higher serum creatinine than their respective
control.
The increase in serum calcium in response to a PTH infusion
is shown in Table I. At both 24 and 48 hours, in thyroid intact
rats, (CT+) CRF versus (CT+) NRF, the increase in serum
calcium was less in renal failure than with normal renal func-
tion. In the two thyroidectomized groups, (CT—) CRF versus
(CT—) NRF, the increase in serum calcium was greater than the
thyroid intact groups, and the calcemic response to PTH was
Fig. 3. The effect of the PTH infusion on the serum calcium concen-
(ration is shown. In renal failure (A), the serum calcium concentration
was greater in the (CT—) CRF () than the (CT+) CRF (0) group at
both 24 and 48 hours. In the two groups with normal renal function, (B)
the serum calcium concentration was greater in the (CT—) NRF (U)
than the (CT+) NRF (0) group at both 24 and 48 hours. Values are the
mean SE. < 0.05
Parathyroid hormone induced hypercalcemia stimulated se-
rum calcitonin levels in thyroid intact (CT+) rats. In the (CT+)
CRF group, the serum calcitonin level increased from 13.5
1.6 to 51.3 12.7 pg/mI during hypercalcemia. Similarly in the
(CT+) NRF group, the serum calcitonin level increased from
9.3 1.3 to 32.4 3.3 pg/mI during hypercalcemia. As shown
in Figure 5, during hypercalcemia, the serum calcitonin levels
were significantly greater in thyroid intact (CT+) rats than their
thyroidectomized (CT—) controls.
The effect of the PTH infusion on the urinary calcium and
phosphorus excretion is shown in Figure 6. Urinary calcium
excretion (6A) was greater in the two thyroidectomized groups,
(CT—) CRF and (CT—) NRF, than their respective controls.
This was likely due to higher serum calcium levels in these two
groups. As shown in Figure 6B, a minimal difference in urinary
phosphorus excretion was observed at 24 hours between the
two groups with renal failure, (CT—) CRF versus (CT+) CRF.
This may have been secondary to differences in serum phos-
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Fig. 4. The effect of the PTH infusion on the serum phosphorus is
shown. In renal failure (A), the serum phosphorus concentration was
significantly greater in the (CT—) CRF (•) than the (CT+) CRF (0)
group at both 24 and 48 hours. In the two groups with normal renal
function (B), the serum phosphorus concentration was similar at all time
intervals [U, (CT—) NRF; LI, (CT+) NRFI. Values are the mean SE.
Discussion
The present study was designed to evaluate whether, in the
presence of hyperparathyroidism and during hypercalcemia,
calcitonin modified the calcemic response to PTH in rats with
normal renal function and rats with renal failure. To determine
the effect of calcitonin, a thyroidectomy was performed in two
groups to eliminate calcitonin production. Hyperparathyroid-
ism was induced by a combination of renal failure and a high
phosphate diet, or in rats with normal renal function, by a high
phosphate diet alone. The results indicate that calcitonin inhib-
ited the calcemic response to PTH both in rats with renal failure
and in rats with normal renal function. Other potential factors
such as differences in renal function, urinary excretion of
calcium, and serum levels of phosphorus, P1'H, and calcitriol
did not appear to play a role.
The infusion of P1'H via a subcutaneously implanted Alzet
pump clearly produced a marked hypercalcemic response. The
design of the study with the use of the same pump for alternate
groups guaranteed that the dose and bioactivity of the PTH was
similar for all groups. Thus, the PTH remained stable for at
least six days and this was likely the result of the preparation of
PTH with 2% cysteine at a pH of 1.5 [14].
Immediately before the P'l'H infusion, the serum phosphorus
concentration, as a result of the high phosphate diet, was
increased both in rats with normal renal function and rats with
renal failure. It has been demonstrated that hyperphosphatemia
can diminish the calcemic response to PTH [10, 22]. However,
although hyperphosphatemia was present at the start of the
48 PTH infusion, no differences were observed in serum phospho-
rus levels. During the PTH infusion, serum phosphorus levels
were greater in the (CT—) CRF than the (CT+) CRF group;
thus, if exerting an effect, the higher serum phosphorus level
should have reduced the calcemic response to PTH in the
(CT—) CRF group. No differences in serum phosphorus levels
were present during the PTH infusion in the two groups with
normal renal function.
A diminished calcemic response to PTH is well described in
renal failure [10—12, 231. In general, this decreased calcemic
response is believed to be secondary to factors resulting from
renal failure. These factors include decreased levels of calcitriol
[111, hyperphosphatemia [10, 22], and down regulation of bone
cell receptors for PTH [12, 23]. In the present study, the mean
serum creatinine level was similar or higher in the groups with
thyroidectomy both before and during the PTH infusion. Thus,
a lesser degree of renal failure could not be the cause of the
greater calcemic response in the two thyroidectomized groups.
Another factor which has been shown to influence the calce-
mic response to PTH is down regulation of bone cell receptors
for PTH. Thus, in renal failure, parathyroidectomy completely
restored the calcemic response to PTH [12, 23], suggesting that
high circulating levels of PTH down regulate bone cell receptors
for PTH. In the present study, PTH levels were similar in the
two groups with renal failure and the two groups with normal
renal function. In both rats with renal failure and normal renal
function, the levels of PTH were considerably higher than we
have previously observed in normal rats [19, 201. This was most
likely due to the combination of renal failure and the high
phosphate diet, or the high phosphate diet alone [18]. Never-
theless, since at the time of PTH infusion, the magnitude of












































Fig. 5. Shown are the serum calcitonin levels obtained during hyper-
calcemia. In renal failure, serum calcitonin levels were significantly
greater in the thyroid intact group, (CT—) CRF vs. (CT+) CRF.
Similarly in the rats with normal renal function, serum calcitonin levels
were greater in the thyroid intact group, (CT—) NRF vs. (CT+) NRF.
* P < 0.05 vs. (CT—) CRF; ** P <0.05 vs. (CT—) NRF
48 ICT—)CRF(CT+)CRF (CT—INRF (CT+l NRF
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hyperparathyroidism was similar in the two groups with renal
failure and the two groups with normal renal function, it seems
unlikely that down regulation of bone cell receptors for PTH
contributed to the observed differences in the calcemic re-
sponse to PTH.
A decrease in urinary calcium excretion could affect the
serum calcium level. However, our findings show that the rats
with the greater magnitude of hypercalcemia excreted more
urinary calcium. Thus, it is unlikely that decreased urinary
calcium excretion contributed to the observed differences in
serum calcium.
Another factor which potentially could influence the calcemic
response to PTH is calcitriol. Several studies have suggested
that pretreatment with calcitriol partially corrects the decreased
calcemic response to PTH in renal failure [11, 24]; however,
other studies have reported no improvement [12, 25]. Known
stimuli for calcitriol include hypophosphatemia [26], PTH [27],
calcitonin [28, 29], and hypocalcemia [30]. In the present study,
none of the above factors except PTH should have stimulated
calcitriol, and the preinfusion PTH levels were not different
between the two groups with renal failure and between the two
groups with normal renal function. In addition, by the 12 to 24
hours required for PTH to stimulate calcitriol production [31], a
marked difference in the calcemic response to PTH was already
observed.
The present study documents for the first time the importance
of calcitonin on the calcemic response to PTH in renal failure.
The absence of calcitonin in the thyroidectomized groups was
documented by radioimmunoassay. During PTH induced hy-
percalcemia, serum calcitonin levels were significantly less in
thyroidectomized rats than their paired controls with intact
thyroid glands. Furthermore, serum calcitonin levels during
hypercalcemia in thyroidectomized rats were even lower than
serum calcitonin levels in their thyroid intact, paired controls,
obtained at normal serum calcium concentrations. The mean
serum calcitonin level of 7.3 pg/mI obtained in thyroidecto-
mized rates with normal renal function, (CT—) NRF, was
similar to levels in thyroidectomized rats reported in another
study using the same calcitonin assay [21]. Finally, stimulated
calcitonin levels were greater in the (CT+) CRF than the (CT+)
NRF group, despite a lower serum calcium concentration in the
former. It is difficult to know whether this difference represents
A Urinary calcium excretion
Chronic renal failure
















Fig. 6. Urinary calcium (A) andphosphorus (B) excretion during the PTH infusion. The results shown are for each time interval and thus are not
cumulative. Both calcium and phosphorus are expressed as a ratio of urinary creatinine. With renal failure and normal renal function, the groups
with higher serum calcium levels and a previous thyroidectomy, (CT—) CRF and (CT—) NRF (U), excreted more calcium at 24 hours (P < 0.05)
and 48 hours than their respective controls (a). Urinary phosphorus excretion was similar at all time intervals except 24 hours at which it was
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bioactivity of calcitonin, or is secondary to an accumulation of
metabolites in renal failure [4, 32, 33]. Although the serum
creatinine levels were comparable after the 48-hour PTH infu-
sion, baseline values were less in the (CT+) NRF group, and
thus could account for some accumulation of calcitonin metab-
olites.
Calcitonin is known to inhibit osteoclasts [34, 35]. Thus, as
suggested by previous clinical studies [36, 37], the observed
differences in the calcemic response to PTH in the present
study may have been due to the fact that in secondary hyper-
parathyroidism, the serum calcium level is dependent on the
number of osteoclasts. In preliminary studies, we have ob-
served that feeding rats with renal failure a high phosphate diet
increased the magnitude of secondary hyperparathyroidism and
induced a marked increase in the number of osteoclasts. Thus,
a possible explanation for the observed differences in the
calcemic response to PTH is that acute hypercalcemia stimu-
lated calcitonin which then inhibited osteoclasts; as a result, the
calcemic response to PTH was decreased.
The calcemic response to PTH was similar in thyroidecto-
mized rats with and without renal failure. Thus, renal failure did
not impair the calcemic response to PTH in rats without
calcitonin. Conversely, differences in the calcemic response to
PTH were observed in thyroid intact rats with renal failure and
rats with normal renal function. Although factors known to
influence the calcemic response such as calcitriol and the
magnitude of down regulation of PTH bone cell receptors may
have been different, these factors did not appear to affect the
calcemic response to PTH in thyroidectomized rats with and
without renal failure. In thyroid intact rats, calcitonin may have
played a role since calcitonin levels were increased in renal
failure. Finally, it should be noted that many previous studies
which have evaluated the factors which modify the calcemic
response to PTH in renal failure were performed in thyropara.
thyroidectomized animals [10—12, 24, 25]. Thus, calcitonin was
not considered as a pathogenic factor. Our results indicate that
in renal failure, calcitonin is an important factor in the de-
creased calcemic response to PTH during PTH induced hyper-
calcemia.
In summary, the present study showed that in renal failure,
the absence of calcitonin increased the calcemic response to
PTH even in the presence of hyperparathyroidism. In the
absence of calcitonin, the calcemic response to PTH was
similar in rats with normal renal function and rats with renal
failure. No known modifiers of the calcemic response such as
the serum phosphorus, serum calcitriol, urinary calcium excre-
tion, or down regulation of bone receptors for PTH, appeared to
account for the findings. In conclusion, in the presence of
hyperparathyroidism and hypercalcemia, calcitonin is an im-
portant modifier of the calcemic response to PTH in the rat,
especially in renal failure. Whether, in the absence of hypercal-
cemia, calcitonin is an important factor in the decreased calce-
mic response to PTH observed in renal failure remains to be
determined.
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